Xencor (XNCR) Competitors

Xencor logo
$34.50 -0.90 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$34.49 -0.01 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XNCR vs. BMRN, TGTX, MDGL, SYRE, and PCVX

Should you buy Xencor stock or one of its competitors? Xencor's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Spyre Therapeutics (SYRE), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xencor compare to BioMarin Pharmaceutical?

Xencor (NASDAQ:XNCR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, BioMarin Pharmaceutical had 4 more articles in the media than Xencor. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 8 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat BioMarin Pharmaceutical's score of 0.30 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioMarin Pharmaceutical has higher revenue and earnings than Xencor. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M20.62-$91.92M-$1.59N/A
BioMarin Pharmaceutical$3.22B3.52$348.90M-$0.10N/A

Xencor currently has a consensus target price of $42.22, suggesting a potential upside of 22.38%. BioMarin Pharmaceutical has a consensus target price of $87.22, suggesting a potential upside of 49.06%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xencor has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of -0.52% compared to Xencor's net margin of -58.79%. BioMarin Pharmaceutical's return on equity of 5.58% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
BioMarin Pharmaceutical -0.52%5.58%3.51%

Summary

BioMarin Pharmaceutical beats Xencor on 12 of the 17 factors compared between the two stocks.

How does Xencor compare to TG Therapeutics?

Xencor (NASDAQ:XNCR) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, TG Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 12 mentions for TG Therapeutics and 8 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat TG Therapeutics' score of 0.67 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

58.6% of TG Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M20.62-$91.92M-$1.59N/A
TG Therapeutics$616.29M15.38$447.18M$0.6695.02

Xencor has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Xencor currently has a consensus price target of $42.22, suggesting a potential upside of 22.38%. TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 0.46%. Given Xencor's higher probable upside, equities analysts clearly believe Xencor is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

TG Therapeutics has a net margin of 11.81% compared to Xencor's net margin of -58.79%. TG Therapeutics' return on equity of 18.82% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
TG Therapeutics 11.81%18.82%7.78%

Summary

TG Therapeutics beats Xencor on 12 of the 15 factors compared between the two stocks.

How does Xencor compare to Madrigal Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Madrigal Pharmaceuticals has a net margin of -10.89% compared to Xencor's net margin of -58.79%. Xencor's return on equity of -21.28% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
Madrigal Pharmaceuticals -10.89%-27.08%-12.04%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xencor presently has a consensus price target of $42.22, suggesting a potential upside of 22.38%. Madrigal Pharmaceuticals has a consensus price target of $706.87, suggesting a potential upside of 67.51%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Madrigal Pharmaceuticals and 8 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat Madrigal Pharmaceuticals' score of 0.22 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Xencor has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

Xencor has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M20.62-$91.92M-$1.59N/A
Madrigal Pharmaceuticals$1.43B6.87-$288.28M-$5.98N/A

Summary

Madrigal Pharmaceuticals beats Xencor on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Xencor (NASDAQ:XNCR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Xencor has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A
Xencor$125.58M20.62-$91.92M-$1.59N/A

Spyre Therapeutics has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market. Comparatively, Xencor has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Spyre Therapeutics currently has a consensus target price of $110.53, suggesting a potential upside of 17.83%. Xencor has a consensus target price of $42.22, suggesting a potential upside of 22.38%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

Spyre Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -58.79%. Xencor's return on equity of -21.28% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -35.97% -27.67%
Xencor -58.79%-21.28%-15.17%

In the previous week, Xencor had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Xencor and 2 mentions for Spyre Therapeutics. Xencor's average media sentiment score of 0.88 beat Spyre Therapeutics' score of 0.56 indicating that Xencor is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Xencor beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to Vaxcyte?

Xencor (NASDAQ:XNCR) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Vaxcyte had 3 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Vaxcyte and 8 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat Vaxcyte's score of 0.68 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xencor has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Xencor presently has a consensus price target of $42.22, suggesting a potential upside of 22.38%. Vaxcyte has a consensus price target of $110.50, suggesting a potential upside of 86.03%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

96.8% of Vaxcyte shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xencor has higher revenue and earnings than Vaxcyte. Xencor is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M20.62-$91.92M-$1.59N/A
VaxcyteN/AN/A-$766.63M-$8.06N/A

Vaxcyte has a net margin of 0.00% compared to Xencor's net margin of -58.79%. Xencor's return on equity of -21.28% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
Vaxcyte N/A -42.04%-36.82%

Summary

Xencor and Vaxcyte tied by winning 8 of the 16 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XNCR vs. The Competition

MetricXencorBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.66B$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E RatioN/A25.6832.7626.82
Price / Sales20.6216.068.565.71
Price / CashN/A22.9521.0121.90
Price / Book4.624.184.463.72
Net Income-$91.92M-$24.15M$3.52B$393.10M
7 Day Performance-12.41%-7.25%-5.47%-4.73%
1 Month Performance50.98%-5.98%-4.57%-7.14%
1 Year Performance120.87%-7.72%-1.79%-7.51%

Xencor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XNCR
Xencor
2.6484 of 5 stars
$34.50
-2.5%
$42.22
+22.4%
+137.1%$2.66B$125.58MN/A260
BMRN
BioMarin Pharmaceutical
4.1151 of 5 stars
$57.09
-0.2%
$87.91
+54.0%
+6.0%$11.05B$3.22BN/A3,221
TGTX
TG Therapeutics
1.9797 of 5 stars
$65.94
+4.0%
$63.00
-4.5%
+102.5%$10.02B$616.29M23.89399
MDGL
Madrigal Pharmaceuticals
4.1114 of 5 stars
$430.95
-0.4%
$706.87
+64.0%
-19.9%$10.01B$958.40MN/A915
SYRE
Spyre Therapeutics
2.4757 of 5 stars
$104.35
-4.3%
$110.53
+5.9%
+322.9%$9.89B$890KN/A130

Related Companies and Tools


This page (NASDAQ:XNCR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners